In the biotech market,
Regeneron Pharmaceuticals (NASDAQ: REGN) has been a hot topic of discussion. The asset possession by numerous firms is noteworthy, with
Callan Family Office LLC buying 1,569 shares,
Amundi acquiring 487,489 shares, and
Wealthfront Advisers LLC and
Andra AP fonden increasing their stock positions. However,
Moran Wealth Management and
Citizens Financial Group have reduced their holdings. The firm is commended by
Jim Cramer, encouraging ownership, despite the stock price being down 1.8% recently. Investors fear that the company has lost its path, prompting ongoing legal investigations, while some hedge funds remain bullish on the oversold blue-chip stock. Contributions to
AI space discovery and
rare disease research have won Regeneron awards. Notably, the Regeneron Science Talent Search 2025 awarded $1.8M to high school seniors for innovative research on classifying celestial bodies, curing a rare muscular illness, and resolving a long-lasting math problem.
Regeneron Pharmaceuticals REGN News Analytics from Fri, 05 Jun 2015 03:14:51 GMT to Sat, 15 Mar 2025 18:46:59 GMT -
Rating 1
- Innovation 8
- Information 9
- Rumor -4
